Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.

Autor: Batteson R; Delta Hat Ltd, Nottingham, UK. rbatteson@deltahat.com., Hook E; Delta Hat Ltd, Nottingham, UK., Wheat H; Delta Hat Ltd, Nottingham, UK., Hatswell AJ; Delta Hat Ltd, Nottingham, UK.; Department of Statistical Science, UCL, London, UK., Vioix H; Global Evidence and Value Department, Merck Healthcare KGaA, Darmstadt, Germany., McLean T; Merck Serono Ltd., an affiliate of Merck KGaA, Feltham, UK., Alexopoulos ST; Merck Serono Ltd., an affiliate of Merck KGaA, Feltham, UK., Baijal S; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Paik PK; Weill Cornell Medical College, New York, NY, USA.; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jazyk: angličtina
Zdroj: Targeted oncology [Target Oncol] 2024 Mar; Vol. 19 (2), pp. 191-201. Date of Electronic Publication: 2024 Mar 16.
DOI: 10.1007/s11523-024-01038-z
Abstrakt: Background: Patients with non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 (METex14) skipping typically demonstrate poorer prognosis than overall non-small cell lung cancer. Until recently, no targeted treatments were available for patients with non-small cell lung cancer harbouring METex14 skipping in the UK, with limited treatments available.
Objective: This study estimates the long-term survival and quality-adjusted life-year benefit of MET inhibitor tepotinib versus current standard of care from a UK perspective.
Methods: A partitioned-survival model assessed the survival and quality-adjusted life-year benefits of tepotinib versus immunotherapy ± chemotherapy and chemotherapy for untreated and previously treated patients, respectively, using evidence from the single-arm VISION trial (NCT02864992). Two approaches were used to inform an indirect treatment comparison: (1) published clinical trials in overall non-small cell lung cancer and (2) real-world evidence in the METex14 skipping population. Results are presented as median and total quality-adjusted life-year gain and survival for progression-free survival and overall survival. Survival curves were validated against the external literature and uncertainty assessed using a probabilistic sensitivity analysis.
Results: Using the indirect treatment comparison against the published literature, tepotinib is estimated to have a median progression-free survival gain versus pembrolizumab ± chemotherapy (11.0 and 9.2 months) in untreated patients, and docetaxel ± nintedanib (5.1 and 6.4 months) in previously treated patients. Across the populations, tepotinib is estimated to have a median survival gain of 15.4 and 9.2 months versus pembrolizumab ± chemotherapy in untreated patients and 12.8 and 5.1 months versus docetaxel ± nintedanib in previously treated patients. The total quality-adjusted life-year gain ranges between 0.56 and 1.17 across the untreated and previously treated populations. Results from the real-world evidence of indirect treatment comparisons are consistent with these findings.
Conclusions: Despite the limitations of the evidence base, the numerous analyses conducted have consistently indicated positive outcomes for tepotinib versus the current standard of care.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: